
Amneal Pharmaceuticals' strong Q3 and pipeline boost buy rating despite risks.
Amneal Pharmaceuticals reported a fourth consecutive earnings beat with Q3 revenue up 10%, leading to higher revenue guidance for fiscal year 2026. The company's growth prospects are supported by its robust drug pipeline, niche market demand, and int...

